The inaugural Prop Masters Guild MacGuffin Awards celebrated the achievements of the artisans who make Hollywood sets come to ...

Oppenheimer started coverage of Dianthus Therapeutics (DNTH) with an outperform rating, citing the market potential of its ...

The show's creator (Oppenheimer) and its newest star (Ellis) tell PEOPLE that "it's strange that it isn't strange" to work ...

Stocks to Watch. In this article, we are going to take a look at where Lowe’s Companies Inc. (NYSE:LOW) stands against the ...

Fintel reports that on October 3, 2024, Oppenheimer initiated coverage of Ligand Pharmaceuticals (NasdaqGM:LGND) with a ...

Fintel reports that on October 3, 2024, Oppenheimer initiated coverage of BridgeBio Pharma (NasdaqGS:BBIO) with a Perform ...

Oppenheimer analyst Scott Schneeberger maintained a Buy rating on XPO (XPO – Research Report) today and set a price target of $140.00.

Oppenheimer analyst Ian Zaffino maintained a Buy rating on Talen Energy Corp (TLN – Research Report) today and set a price target of ...

Cillian Murphy once shared his “Catholic guilt” for making $10 million from Christopher Nolan’s Oppenheimer, admitting he ...

We look at prior dramatizations of this very complicated man—including one wherein J. Robert Oppenheimer played himself!—and examine why they worked or didn't. In this episode: ...

We look at prior dramatizations of this very complicated man—including one wherein J. Robert Oppenheimer played himself!—and examine why they worked or didn't. In the episode: ...

Oppenheimer has recently initiated Cadence Design Systems Inc (CDNS) stock to Underperform rating, as announced on September 25, 2024, according to Finviz. Earlier, on August 6, 2024, Piper Sandler ...